The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a ...
Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...
I’M Dr Suraj Kukadia, known as Dr Sooj, an NHS GP who has seen how life-changing COPD can be. As the colder months set in, I ...
The FDA approved nerandomilast tablets for adults with progressive pulmonary fibrosis, according to an industry press release ...
Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...
The FDA today approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of progressive pulmonary fibrosis (PPF ...
Dailymotion on MSN
How many Australians have COPD and don't know?
Australians with a debilitating and sometimes deadly lung disease may be missing out on early detection and treatment, with ...
A baby born in Van, eastern Türkiye, almost seven months ago with an underdeveloped right side of the heart, has regained ...
Mepolizumab reduced COPD exacerbations in patients with eosinophilic inflammation, highlighting the potential of ...
Doctronic reports chest colds last 7-14 days, caused by viral infections or irritants, with symptoms like cough and chest ...
Zacks Investment Research on MSN
GSK's Nucala for COPD and Depemokimab for asthma get CHMP nod in EU
GSK plc GSK announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback